Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Everolimus stent: Additional Phase III data

Data from the first 30 patients enrolled in the open-label, international Phase III ABSORB

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE